How Long Does Wegovy Prior Authorization Take? Real Timelines and the Appeal Strategy That Works

Direct answer (40-60 words)

Wegovy prior authorization typically takes 3 to 14 calendar days for a routine decision and 24 to 72 hours for an expedited request. Denials add another 30 to 45 days for the appeal process. The timeline depends on how complete the submitted documentation is and whether your plan requires step therapy or weight loss attempts.

Table of contents

1. The 30-second answer
2. What prior authorization actually is
3. Standard vs expedited timelines
4. What insurance plans require for Wegovy approval
5. Why most Wegovy PAs are denied the first time
6. The appeal process: levels and timelines
7. How to speed up your PA
8. What happens after approval (and why it's not always permanent)
9. Compounded semaglutide as an alternative
10. FAQ
11. Footer disclaimers

What prior authorization actually is

Prior authorization (PA) is the insurance industry's review process for medications it considers expensive, restricted, or off-formulary. The pharmacy can't dispense the drug until the plan's reviewer signs off on the request. For Wegovy specifically, almost every commercial plan and most Medicare Part D plans require PA because of the cost (roughly $1,350 retail per month) and because of step-therapy requirements.

The process has four parties:

1. The patient. You need a prescription from a licensed provider and complete medical records.
2. The provider. Submits the PA request with supporting documentation.
3. The insurer (or pharmacy benefit manager). Reviews the request against the plan's criteria.
4. The pharmacy. Holds the prescription until PA approval comes through.

The PA decision is binary: approved (medication is covered, copay applies) or denied (you can pay cash, switch to a different drug, or appeal). A denial isn't the end of the road. About 60% of initial Wegovy PA denials are overturned on first-level appeal when the appeal includes the right documentation.

Standard vs expedited timelines

Insurance plans operate on two PA tracks: standard and expedited. The difference matters because Wegovy patients often have urgent reasons (worsening obesity-related comorbidities, surgical clearance, gestational planning) that justify expedited review.

Standard prior authorization (most cases):

Day	Milestone
0	Provider submits PA request with documentation
1-3	Insurer acknowledges receipt
3-7	Reviewer assesses against plan criteria
7-14	Decision rendered (most plans)
14-30	Some complex cases or documentation requests can extend this

Federal regulations require commercial plans to render a standard PA decision within 14 calendar days of receiving complete documentation. State-regulated plans (HMOs, ACA marketplace plans) often have stricter timelines, sometimes 7 days.

Expedited prior authorization:

Day	Milestone
0	Provider submits PA marked "expedited" with clinical justification
24-72 hours	Decision rendered

Expedited PA is reserved for cases where standard review would jeopardize the patient's health. For Wegovy specifically, "jeopardize health" is interpreted narrowly. Acceptable justifications include:

• Acute obesity-related comorbidity (uncontrolled diabetes, severe sleep apnea, cardiovascular event)
• Pre-surgical weight optimization with a near-term surgery date
• Failed bariatric surgery requiring medical management

"My weight is causing me distress" or "I've been waiting six months" are not typically accepted as expedited justifications. Your provider has to make a clinical case that delay would cause harm.

What insurance plans require for Wegovy approval

The PA criteria for Wegovy are reasonably consistent across major insurers, though specifics vary. Most plans require:

BMI requirements:

• BMI 30 or higher (obesity), or
• BMI 27 to 29.9 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, sleep apnea, cardiovascular disease)

Documented prior weight loss attempts:

• 3 to 6 months of medically supervised diet and exercise
• Often documented in chart notes from a primary care or specialist visit
• Sometimes requires participation in a structured weight management program (like the Diabetes Prevention Program or a hospital-based weight clinic)

Step therapy (sometimes):

• Failure of at least one alternative weight management medication (phentermine, naltrexone-bupropion, orlistat) before Wegovy
• Some plans accept "contraindication" rather than "trial and failure" if the alternatives aren't appropriate

Age requirements:

• Adults (18+) for the Wegovy weight management indication
• Adolescents (12-17) for the pediatric obesity indication, with additional documentation
• Cardiovascular risk reduction indication added in 2024 has its own criteria

Provider type:

• Most plans accept primary care providers as prescribers
• Some plans require an obesity specialist, endocrinologist, or weight management clinic for initial PA
• Telehealth providers are accepted by most major plans, though specifics vary

The common reason PAs get rejected is missing documentation, not failing the criteria. Plans want to see specific chart notes, weight history, BMI calculation, prior medication trials, and the prescribing rationale. A complete first submission saves weeks compared to a thin submission that gets sent back for more information.

Why most Wegovy PAs are denied the first time

The denial rate for initial Wegovy PA varies widely (some plans deny 30%, others 70%), but the reasons cluster into a small number of categories.

Reason 1: Missing or insufficient weight-loss attempt documentation. The plan wants 3 to 6 months of documented attempts. If your medical record doesn't have a clear log of dietary changes, exercise programs, and weights at multiple visits, the PA gets denied. This is the most common denial reason.

Reason 2: BMI doesn't meet plan threshold. If you're at BMI 28 without a documented comorbidity, or at BMI 29.5 borderline, the PA may be denied because the plan reads the criteria strictly.

Reason 3: Step therapy failure not documented. Plans that require trying phentermine or another medication first need that documented in your chart. "Patient declined" doesn't count; the plan wants documented trial.

Reason 4: Comorbidity not documented in current chart. A history of hypertension from 5 years ago doesn't count if it's not currently active. Plans want recent labs, current diagnoses, and active treatment.

Reason 5: Off-formulary status. Some plans simply don't cover Wegovy at all. In that case, no amount of documentation gets you to approval through the normal PA process. You need a formulary exception, which is a separate appeal.

Reason 6: Coverage exclusion for "weight management." Some employer plans specifically exclude weight loss medications. You can find this in the Evidence of Coverage document. If weight management is excluded, only the cardiovascular indication might be covered, and even that depends on the plan.

A denial letter usually includes the specific reason. Read it carefully. The path to approval almost always involves submitting the missing documentation rather than fighting the criteria.

The appeal process: levels and timelines

When the initial PA is denied, you have appeal rights. Most plans have three levels.

Level 1 (internal appeal):

• Submitted by your provider with additional documentation
• Plan must respond within 30 calendar days for a non-urgent appeal, 72 hours for an expedited appeal
• Most successful appeals win at this level

Level 2 (internal appeal, second review):

• If level 1 is denied, request a second internal review
• Often reviewed by a different clinician or a peer-to-peer (your provider speaks directly with the plan's medical director)
• 30 days standard, 72 hours expedited

Level 3 (external review):

• Independent third-party review, ordered after both internal levels exhausted
• Required by federal law (ACA) for most commercial plans
• 45 days standard, 72 hours expedited
• Decision is binding on the insurer

The peer-to-peer call at level 2 is often the most effective step. A provider on the phone with the plan's medical director can explain the clinical case in a way that text submissions can't. Most providers know to request a peer-to-peer at the level 2 stage if the level 1 denial cited a clinical issue.

The total appeal timeline can run 60 to 90 days from initial denial to external review decision. Plan accordingly. If you're waiting on Wegovy and the appeal is in process, ask your provider whether a different medication can be prescribed in the interim or whether compounded semaglutide is appropriate.

How to speed up your PA

A few practical steps that meaningfully reduce the time from prescription to approval:

Document weight loss attempts before the prescription. Six months of monthly visits with logged weights, food diaries, and exercise tracking is the gold standard. Even three months of clear documentation works. Without this, your PA will likely fail and you'll need to backfill the documentation during the appeal.

Have current labs and comorbidity diagnoses on file. A complete metabolic panel, lipid panel, A1c (if diabetic), and current BP readings within the last 6 months are usually expected. If your plan has step-therapy requirements, document the prior medication trial in your chart.

Use a provider experienced with PA submissions. Some primary care offices, weight management clinics, and telehealth platforms specialize in obesity medication and have streamlined PA workflows. They know what your specific insurer wants. A provider who submits Wegovy PAs weekly is faster than one who's never done it.

Submit electronically when possible. Most major insurers accept electronic PA submissions through their provider portal or through services like CoverMyMeds, ePA, or Surescripts. Electronic submission cuts 1 to 3 days off the timeline compared to fax.

Ask the pharmacy to start the PA at the prescription, not at pickup. Some pharmacies notify the prescriber to initiate PA the moment the prescription arrives, rather than waiting for the patient to come pick it up. This saves a few days.

Request expedited if clinically appropriate. If you have a near-term surgery, an acute comorbidity flare, or a documented urgent need, ask your provider to mark the PA expedited. The clinical justification has to be real.

Have a backup plan. Even if everything is in order, PAs occasionally fall through administrative cracks. If approval doesn't come through within 14 days, your provider should follow up with the insurer's PA hotline.

What happens after approval (and why it's not always permanent)

PA approval isn't necessarily permanent. Most Wegovy approvals are granted for 6 or 12 months and require renewal.

Renewal criteria:

• Most plans require evidence of weight loss progress (often 5% body weight loss within the first 6 months)
• Continued comorbidity management
• Confirmation of adherence to the medication

If you haven't lost 5% within 6 months, some plans will deny renewal. This is an evidence-based threshold tied to the SELECT and STEP trial outcomes that supported approval.

Dose escalation PAs:

Wegovy titrates from 0.25 mg up to 2.4 mg over about 16 weeks. Some plans require a separate PA at each dose escalation. Others approve once at the maintenance dose and don't require additional PA for titration. Check with your provider on what your specific plan requires.

Formulary changes:

Insurance plans update their formularies annually, sometimes mid-year. A medication that's covered today may be moved to a higher tier or excluded entirely next year. If you're on Wegovy and your plan changes its formulary, you'll receive notice. Sometimes the plan grandfathers existing patients; sometimes it doesn't.

Compounded semaglutide as an alternative

When Wegovy PA fails or is exhausted, compounded semaglutide is one alternative path. The clinical and regulatory differences:

Clinical:

• Same active ingredient (semaglutide)
• Different dosing presentation (multi-dose vial vs single-dose pen)
• Compounded preparations are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality
• Outcomes data is more limited than for branded Wegovy

Cost:

• Compounded semaglutide programs typically run $179 to $329 per month, paid out of pocket
• No PA required because no insurance is involved
• Pricing is predictable month over month

Access:

• Provider visit and prescription required
• Dispensed by state-licensed compounding pharmacies
• Mail-order delivery is standard

Regulatory caveats:

• Compounded semaglutide is not interchangeable with Wegovy
• The FDA has expressed safety concerns about some compounded formulations
• Always use a state-licensed compounding pharmacy with USP 797 compliance and verify your provider has reviewed the pharmacy's quality program

For patients facing extended PA delays or denials, compounded semaglutide is a working option to discuss with a clinician. (See our compounded semaglutide cost guide for current pricing comparison and our GLP-1 storage guide for handling vials at home.)

FAQ

How long does prior authorization take for Wegovy?

Standard PA usually takes 3 to 14 calendar days. Expedited PA, when clinically justified, takes 24 to 72 hours. If denied, the appeal process can add 30 to 90 days.

Why does Wegovy require prior authorization?

Wegovy is expensive (around $1,350 retail per month), and insurers require documentation that the medication is medically appropriate before approving coverage. PA criteria typically include BMI thresholds, comorbidity documentation, and prior weight loss attempts.

What documents do I need for a Wegovy PA?

Typically: prescription, current BMI calculation, 3 to 6 months of documented weight loss attempts, current labs (metabolic panel, lipid panel, A1c if diabetic), comorbidity diagnoses, and (for some plans) documentation of prior medication trials.

What happens if my Wegovy PA is denied?

You have appeal rights. The first appeal is typically internal to the insurer (level 1). If denied, you can request a second internal review (level 2, often with peer-to-peer). If denied again, you can request external review (level 3), which is binding on the insurer. About 60% of initial denials are overturned on appeal with adequate documentation.

Can I get Wegovy without prior authorization?

You can buy Wegovy at retail price (around $1,350 per month) without PA. Some discount cards (the Novo Nordisk savings card for commercially insured patients without coverage) reduce the cash price. Without commercial insurance, the savings card may not apply.

Does Medicare cover Wegovy?

Medicare Part D coverage for Wegovy expanded in 2024 for cardiovascular risk reduction in patients with obesity and existing cardiovascular disease. Coverage for weight management alone is more limited. PA requirements vary by plan.

Will my employer plan cover Wegovy?

About 30 to 40% of employer plans cover Wegovy as of 2026. Some employers have specifically excluded weight management medications from their plan design. Check your Evidence of Coverage or summary of benefits, or call the plan directly to ask whether Wegovy is on formulary and what tier.

How do I know if my plan requires step therapy for Wegovy?

Look at the plan's formulary or PA criteria document. If step therapy is required, you'll need documented trials of cheaper alternatives (typically phentermine, orlistat, or naltrexone-bupropion) before Wegovy will be approved. Your provider can also call the PA hotline to ask.

Can my doctor request expedited PA?

Yes, if there's a clinical justification. Examples include acute obesity-related comorbidity, pre-surgical weight optimization, or failed bariatric surgery. The provider needs to document why standard timelines would harm the patient.

What's a peer-to-peer review?

A direct conversation between your prescriber and the insurer's medical director. Often available at level 2 of the appeal process. Effective when the denial is based on clinical criteria the prescriber can address verbally that aren't easy to communicate in text.

How often does Wegovy PA need to be renewed?

Most plans approve for 6 or 12 months at a time. Renewal usually requires evidence of progress (often 5% body weight loss in the first 6 months). Some plans have additional PA requirements at dose escalations.

What should I do while waiting for PA approval?

Stay engaged with your provider. If approval doesn't come within 14 days, ask the office to follow up with the insurer. Don't pay cash for Wegovy unless you've decided that's the right option (savings card may help if you have commercial insurance). Compounded semaglutide is one option to discuss if PA is delayed or denied.

Author / review note

Reviewed by the FormBlends Medical Team. References include the Wegovy FDA-approved prescribing information (Novo Nordisk, latest revision), Centers for Medicare & Medicaid Services PA timeline regulations, Affordable Care Act external review provisions, and the American Medical Association Prior Authorization Reform Initiative materials.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. CoverMyMeds and Surescripts are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by these companies.